06:27 , Aug 10, 2018 |  BC Week In Review  |  Company News

China Medical gains rights to Can-Fite's ADORA3 agonists

CMS Medical Venture Investment Ltd. gained rights to develop and commercialize piclidenoson (CF101) and namodenoson (CF102) in Taiwan and China, including Hong Kong and Macau, from Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-A:CANF). Can-Fite received $2 million...
14:13 , May 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Cell culture and mouse studies identified adenosine-based dual-acting ADORA1 agonists/ADORA3 antagonists that could help treat pain. Chemical synthesis and testing of adenosine analogs in cell-based receptor binding and activity assays yielded three compounds that...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

Piclidenoson: Phase II data

Top-line data from a double-blind, international Phase II trial in 89 patients with ocular hypertension and/or glaucoma showed that twice-daily oral CF101 missed the primary endpoint of reducing IOP from baseline to week 16 vs....
07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

CF102 regulatory update

FDA granted Fast Track designation to Can-Fite’s CF102 as a second-line treatment for hepatocellular carcinoma (HCC). The nucleoside adenosine A3 receptor (ADORA3) agonist is in Phase II testing to treat HCC and has Orphan...
07:00 , May 11, 2015 |  BC Week In Review  |  Clinical News

IB-MECA: Additional Phase II/III data

Additional data from a double-blind, international Phase II/III trial in 326 patients with moderate to severe plaque psoriasis showed that twice-daily oral CF101 led to a 57% mean improvement in PASI score from baseline to...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Company News

Can-Fite, Cipher deal

Can-Fite granted Cipher rights to commercialize Can-Fite’s CF101 in Canada to treat moderate to severe psoriasis and rheumatoid arthritis. The adenosine A3 receptor (ADORA3) agonist has completed a Phase II/III trial to treat...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Clinical News

IB-MECA: Phase II/III data

Top-line data from a double-blind, international Phase II/III trial in 326 patients with moderate to severe plaque psoriasis showed that twice-daily oral CF101 missed the primary endpoint of improving PASI 75 response rate at week...
07:00 , Apr 6, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg4/2 clsCan-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF)ROTH Capital PartnersJoseph PantginisDowngradeNeutral (from buy)-58%$2.32 Pantginis also lowered his target to $2.40 from $20 after Can-Fite reported that CF101 missed the...
08:00 , Feb 5, 2015 |  BC Innovations  |  Product R&D

Addex's allosterics

Allosteric modulators are slowly filling the clinical pipeline, but finding the right assays to discover and characterize them properly still confounds companies in the space. Addex Therapeutics Ltd. is going back to basics and forging...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Clinical News

CF102: Phase II started

Can-Fite began a double-blind, placebo-controlled, international Phase II trial to evaluate 25 mg oral CF102 twice daily in about 78 HCC patients with Child-Pugh Class Beta cirrhosis who failed first-line treatment with Nexavar sorafenib....